Mycotopia Therapies Files 8-K with Material Agreements

TL;DR

MYCO just filed an 8-K detailing material agreements and corporate changes. Keep an eye on this one.

AI Summary

Mycotopia Therapies, Inc. filed an 8-K on July 29, 2024, reporting a material definitive agreement and amendments to its articles of incorporation. The company, formerly known as 20/20 Global, Inc., is incorporated in Nevada and operates in the medicinal chemicals and botanical products sector. The filing also includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate actions and agreements by Mycotopia Therapies, Inc., which could impact its business operations and future financial performance.

Risk Assessment

Risk Level: medium — The filing indicates material definitive agreements and amendments, which can introduce new risks or opportunities that are not yet fully understood.

Key Numbers

• 20190102 — Name Change Date (Indicates when the company officially changed its name from 20/20 Global, Inc.)
• 1231 — Fiscal Year End (Specifies the end of the company's fiscal year for financial reporting.)

Key Players & Entities

• Mycotopia Therapies, Inc. (company) — Registrant
• 20/20 Global, Inc. (company) — Former company name
• July 29, 2024 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of Incorporation
• 000-56022 (filing_id) — SEC File Number

FAQ

Filing Documents

• tpia-20240729.htm (8-K) — 22KB
• tpia_ex3z1.htm (EX-3.1) — 2KB
• tpia_ex3z2.htm (EX-3.2) — 23KB
• tpia_ex10z1.htm (EX-10.1) — 23KB
• tpiaex3z1_1.jpg (GRAPHIC) — 329KB
• tpiaex3z1_2.jpg (GRAPHIC) — 352KB
• tpiaex3z1_3.jpg (GRAPHIC) — 659KB
• tpiaex3z1_4.jpg (GRAPHIC) — 506KB
• tpiaex3z1_5.jpg (GRAPHIC) — 136KB
• 0001096906-24-001786.txt ( ) — 2940KB
• tpia-20240729_def.xml (EX-101.DEF) — 2KB
• tpia-20240729_lab.xml (EX-101.LAB) — 20KB
• tpia-20240729_pre.xml (EX-101.PRE) — 13KB
• tpia-20240729.xsd (EX-101.SCH) — 2KB
• tpia-20240729_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On July 29, 2024, the Mycotopia Inc. (the "Company") entered into an Exchange Agreement with Ehave Inc., its largest shareholder, whereby Ehave exchanged 9,793,754 shares of Company common stock for 1 share of the newly designated Series A Super Voting Stock ("Series A Preferred"). The holder of the Series A Preferred is entitled to cast that number of votes on all matters presented for stockholder vote to the stockholders of the Corporation that when taking into account the votes entitled to be cast by the Series A Preferred stockholder is equal to seventy-five percent (75%) of the total shares authorized to vote on such matter(s) and such holder shall vote along with holders of the Corporation's Common Stock on such matters. The number of votes that the holder of the Series A Preferred shares shall be entitled to cast on a matter at any time shall be determined pursuant to the following formula: X = 3 x Y where X is the total number of votes that the holder of the Series A Preferred share is entitled to cast on any matter presented to stockholders of the Corporation, and Y is the total number of authorized shares of the Corporation outstanding and authorized to vote on the matter. Additionally, the Series A Preferred Stock is convertible into 9,793,754 shares of Company common stock at the option of the holder. The description of the designation of the Series A Preferred stock and the Exchange Agreement contained herein are each qualified in their entirety by reference to the designation for the Series A Preferred and the Exchange Agreement attached hereto as exhibits.

03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On June 24, 2024, the Board of Directors of the Company approved the designation of the Series A Super Voting Stock, the Exchange Agreement with Ehave, Inc., and an amendment to the Company's articles of incorporation increasing the number of authorized shares of common stock to 467,000,000 (Four Hundred Sixty-Seven Million). The designation of the Series A Preferred and the amendment increasing the authorized common stock were filed with the state of Nevada on August 8, 2024. The description of the designation of the Series A Preferred stock contained herein is qualified in its entirety the by reference to the designation for the Series A Preferred attached hereto as an exhibit.

01 FINANCIAL STATEMENTS AND EXHIBITS

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS Exhibit No. Description 3.1 Amendment to Articles of Incorporation Increasing Authorized 3.2 Designation of Series A Super Voting Preferred Stock 10.1 Exchange Agreement with Ehave Inc.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mycotopia Therapies, Inc. a Nevada corporation Date: August 20, 2024 By: /s/Ben Kaplan Name: Ben Kaplan Title: Chief Executive Officer and Principal Accounting Officer

View Full Filing

View this 8-K filing on SEC EDGAR